|
|
AbbVie Files Form 8-K
NORTH CHICAGO, ILLINOIS, U.S.A., May 10, 2016 - AbbVie Inc. ("AbbVie") (NYSE /
CHX / Euronext Paris / SIX: ABBV) today informs its stockholders that it has
filed a Periodic Report on Form 8-K with the U.S. Securities and Exchange
Commission ("SEC") announcing the voting results of its Annual Meeting of
Stockholders held on May 6, 2016.
AbbVie makes available... Lire le communiqué |
|
| |
|
| |
|
|
AbbVie Files Form 8-K
NORTH CHICAGO, ILLINOIS, U.S.A., May 6, 2016 - AbbVie Inc. ("AbbVie") (NYSE /
CHX / Euronext Paris / SIX: ABBV) today informs its stockholders that it has
filed a Periodic Report on Form 8-K/A with the U.S. Securities and Exchange
Commission ("SEC") amending the April 25, 2016 announcement regarding the
Agreement and Plan of Merger (the "Merger Agreement") with... Lire le communiqué |
|
| |
|
| |
|
|
AbbVie Files Form 10-Q
NORTH CHICAGO, ILLINOIS, U.S.A., May 6, 2016 - AbbVie Inc. ("AbbVie") (NYSE /
CHX / Euronext Paris / SIX: ABBV) today informs its stockholders that it has
filed a Quarterly Report on Form 10-Q for the quarter ended March 31, 2016 with
the U.S. Securities and Exchange Commission ("SEC").
AbbVie makes available free of charge on its website its Annual Report on... Lire le communiqué |
|
| |
|
| |
|
|
AbbVie Files Form 8-K
NORTH CHICAGO, ILLINOIS, U.S.A., April 29, 2016 - AbbVie Inc. ("AbbVie") (NYSE /
CHX / Euronext Paris / SIX: ABBV) today informs its stockholders that it has
filed a Periodic Report on Form 8-K with the U.S. Securities and Exchange
Commission ("SEC") announcing that on April 25, 2016, AbbVie entered into an
Agreement and Plan of Merger (the "Merger Agreement") with... Lire le communiqué |
|
| |
|
| |
|
|
AbbVie Reports First-Quarter 2016 Financial Results
- Reports First-Quarter Adjusted Diluted EPS of $1.15, Up 22.3 Percent; GAAP
Diluted EPS of $0.83
- Delivers First-Quarter Net Revenues of $5.96 Billion, an Increase of 22.4
Percent Over First-Quarter 2015 on an Operational Basis; Reported Net Revenues
Increased 18.2 Percent
- Delivers Adjusted Operating Margin Expansion to 43.1... Lire le communiqué |
|
| |
|
| |
|
|
AbbVie to Expand Oncology Presence Through Acquisition of Stemcentrx and its
Novel, Late- Stage Rova-T Compound for Small Cell Lung Cancer
- Rovalpituzumab tesirine (Rova-T) is a biomarker-specific antibody drug
conjugate targeting cancer stem cell protein DLL3
- Compelling data on Rova-T was presented at the European Society of Medical
Oncology demonstrating overall response rates of 44... Lire le communiqué |
|
| |
|
| |
|
|
AbbVie Files Definitive Proxy Statement on Schedule 14A
NORTH CHICAGO, ILLINOIS, U.S.A., March 21, 2016 - AbbVie Inc. ("AbbVie")
(NYSE / CHX / Euronext Paris / SIX: ABBV) today informs its stockholders that
it has filed a definitive proxy statement on Schedule 14A with the U.S.
Securities and Exchange Commission ("SEC").
AbbVie makes available free of charge on its website its... Lire le communiqué |
|
| |
|
| |
